Drug news
FDA issues Complete Response Letter for Zynquista to treat type 1 diabetes
The FDA has issued a Complete Response Letter (CRL) regarding the New Drug Application for investigational Zynquista (sotagliflozin), a dual SGLT1 and SGLT2 inhibitor from Sanofi + Lexicon, for the treatment of adults with type 1 diabetes in combination with insulin. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form.
Sanofi and Lexicon will work closely with the FDA to determine the appropriate next steps.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.